Home / Market News / $AGEN
benzinga Corporate Catalyst Impact 75/100 ● positive

Reported Saturday, Agenus Says 25% Of Recurrent Ovarian Cancer Patients Treated With BOT+BAL Were Alive And Off All Therapy At Last Follow-Up, With 48% Estimated Three-Year Survival Among Evaluable Patients

Oct 5, 2026, 6:57 AM UTC · Primary ticker $AGEN

Agenus reported positive long-term survival data for its BOT+BAL treatment in recurrent ovarian cancer patients, demonstrating a 48% estimated three-year survival rate. This data suggests a durable benefit in a heavily pretreated and difficult-to-treat patient population, potentially enhancing the drug's market prospects and Agenus's valuation.

Agenus announced encouraging long-term survival data for its BOT+BAL combination therapy in recurrent ovarian cancer. The 48% estimated three-year survival rate and the fact that 25% of patients were alive and off therapy are significant, especially given the patient population's heavy pretreatment and platinum-resistant/refractory status. This positive data could lead to increased investor confidence and potentially accelerate regulatory pathways or partnership opportunities for Agenus, offering a long-term positive outlook for the company. For traders, this presents an opportunity for a short-term upward price movement in AGEN shares, with the long-term implications tied to further clinical development and commercialization success.

$AGEN positive Positive clinical trial data
Source: benzinga
Join the waitlist for full signal validation →

Not financial advice. AI-generated analysis for informational purposes only.